Singapore, July 14 -- South Korea-based contract development and manufacturing organisation (CDMO) Samsung Bioepis has published a whitepaper titled 'Solving the Biosimilar Void in Europe' that proposes policy recommendations to fully recognise the value of biosimilars and ensure a more sustainable market in Europe.

Biosimilars have played a significant role in alleviating the financial burden on the European healthcare system, having delivered €56 billion in cumulative cost savings across Europe over the past 11 years (2013-2024).However, the current policy environment in Europe, particularly the post-launch pathways, is misaligned to incentivise biosimilar competition. With post-marketing challenges, on top of high development co...